Design and Rationale of the APELOT Trial: A Randomized, Open-Label, Multicenter, Phase IV Study to Evaluate the Antiplatelet Effect of Different Loading Dose of Ticagrelor in Patients With Non-ST Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Ticagrelor is a direct acting on the P2Y12 receptor blocker, which provides faster and greater platelet inhibition than clopidogrel. However, several studies suggested that in ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention (PCI), ticagrelor exhibits...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hui-Liang, Wei, Yu-Jie, Jin, Zhi-Geng, Zhang, Jiao, Ding, Peng, Yang, Sheng-Li, Luo, Jian-Ping, Ma, Dong-Xing, Liu, Ying, Han, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
3400
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900712/
https://www.ncbi.nlm.nih.gov/pubmed/27258504
http://dx.doi.org/10.1097/MD.0000000000003756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900712/
https://www.ncbi.nlm.nih.gov/pubmed/27258504
http://dx.doi.org/10.1097/MD.0000000000003756

Ejemplares similares